- Home
- RBOT vs IFRX Comparison
RBOT vs IFRX Comparison
Compare RBOT & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RBOT | IFRX |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9M | 60.6M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | RBOT | IFRX |
|---|---|---|
| Price | $1.98 | $0.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $7.00 | ★ $8.50 |
| AVG Volume (30 Days) | 63.3K | ★ 171.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,054.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.71 | $0.71 |
| 52 Week High | $13.75 | $1.94 |
Technical Indicators
Market Signals| Indicator | RBOT | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.38 | 52.69 |
| Support Level | $1.76 | $0.75 |
| Resistance Level | $2.41 | $1.16 |
| Average True Range (ATR) | 0.20 | 0.07 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 38.63 | 50.85 |
Price Performance
Historical ComparisonAbout RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.